Xenetic Biosciences, Inc. (XBIO) stock
XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3069% below fair value
$1.40−0.14 (-9.09%)
Close on Nov 20, 2026Market cap $3.28MP/E –Yield –
Xenetic Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Xenetic Biosciences's free cash flow for the twelve months ending Dec 31, 2018 was -$6.46M, down 535.3% year over year. For fiscal 2018 it was -$6.46M, down 535.3% from the year before. The highest annual figure on record is $1.48M in fiscal 2017.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | -$6.46M | -535.3% |
| FY2017 | Dec 31, 2017 | $1.48M | – |
| FY2016 | Dec 31, 2016 | -$8.80M | – |
| FY2015 | Dec 31, 2015 | -$5.30M | – |
| FY2014 | Dec 31, 2014 | -$12.74M | – |
| FY2013 | Dec 31, 2013 | -$6.13M | – |
| FY2012 | Dec 31, 2012 | -$6.39M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018 | Dec 31, 2018 | -$1.04M | -121.5% |
| Q3 FY2018 | Sep 30, 2018 | -$1.67M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.67M | -705.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $275.38K | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.63M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.03M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.36M | – |
See a number that looks wrong?